Halozyme Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Halozyme Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About HALO

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. 

CEO
Helen I. Torley
CEOHelen I. Torley
Employees
423
Employees423
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1998
Founded1998
Employees
423
Employees423

HALO Key Statistics

Market cap
7.60B
Market cap7.60B
Price-Earnings ratio
25.07
Price-Earnings ratio25.07
Dividend yield
Dividend yield
Average volume
1.27M
Average volume1.27M
High today
$66.36
High today$66.36
Low today
$64.01
Low today$64.01
Open price
$65.44
Open price$65.44
Volume
1.65M
Volume1.65M
52 Week high
$82.22
52 Week high$82.22
52 Week low
$47.50
52 Week low$47.50

Stock Snapshot

Halozyme Therapeutics(HALO) stock is priced at $64.69, giving the company a market capitalization of 7.6B. It carries a P/E multiple of 25.07.

On 2026-05-09, Halozyme Therapeutics(HALO) stock moved within a range of $64.01 to $66.36. With shares now at $64.69, the stock is trading +1.1% above its intraday low and -2.5% below the session's peak.

Trading activity shows a volume of 1.65M, compared to an average daily volume of 1.27M.

Over the past 52 weeks, Halozyme Therapeutics(HALO) stock has traded between a high of $82.22 and a low of $47.50.

Over the past 52 weeks, Halozyme Therapeutics(HALO) stock has traded between a high of $82.22 and a low of $47.50.

HALO News

TipRanks 2d
Halozyme Stockholders Back Board, Pay and Auditor Choices

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

TipRanks 2d
Halozyme announces global collaboration and license agreement with GSK

Halozyme Therapeutics (HALO) announced the company entered into a global collaboration and license agreement with GSK (GSK). Under the collaboration, GSK has li...

Simply Wall St 6d
The Bull Case For Halozyme Therapeutics Could Change Following Ex-J&J CFO Hire – Learn Why

Halozyme Therapeutics, Inc. recently announced that Darren Snellgrove will become Chief Financial Officer on June 8, 2026, taking charge of the company’s financ...

The Bull Case For Halozyme Therapeutics Could Change Following Ex-J&J CFO Hire – Learn Why

Analyst ratings

60%

of 10 ratings
Buy
60%
Hold
30%
Sell
10%

People also own

Based on the portfolios of people who own HALO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.